NCT02956382 - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

May 23, 2023

Study Completion Date

March 7, 2024

Conditions

Refractory Follicular LymphomaRelapsed Follicular Lymphoma

Interventions

DRUG

Ibrutinib

Ibrutinib is dispensed as a capsule.

DRUG

Venetoclax

Venetoclax is dispensed as a tablet.

Trial Locations (3)

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Seattle Cancer Care Alliance, Seattle

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack